Home Uncategorized Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for... Uncategorized Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer By Ogkologos - August 25, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENZAMET (ANZUP 1304) study Source RELATED ARTICLESMORE FROM AUTHOR Saving Time for Patients and Improving Well-Being Through Mindfulness and Fitness: Research from the 2023 ASCO Quality Care Symposium FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer with a BRAF V600E Mutation Engaging People with Low-Grade Glioma in Cancer Research MOST POPULAR Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... September 10, 2025 Cancer in My Community: Addressing Regional Cancer Disparities in Peru August 24, 2023 Adding Tremelimumab to Durvalumab and Chemotherapy Provides Survival Benefit for Patients... November 15, 2022 FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple... July 14, 2021 Load more HOT NEWS Manageable Safety Profile and Antitumour Activity of Zongertinib in Pretreated Patients... First Prospective Description of Familial EGFR-mutated Lung Cancer Living with a stoma: Neil and Lindsay share their experiences after... Can Eating Soy Cause Breast Cancer?
